Abstract-Effects of a new angiotensin-converting enzyme inhibitor, N-[3-(N cyclohexanecarbonyl D-alanylthio)-2-methylpropanoyl]-L-proline calcium (MC 838), on the systemic and coronary circulation were evaluated in anesthetized dogs, and the effects were compared with those of captopril.
Abstract-Effects of a new angiotensin-converting enzyme inhibitor, N-[3-(N cyclohexanecarbonyl D-alanylthio)-2-methylpropanoyl]-L-proline calcium (MC 838), on the systemic and coronary circulation were evaluated in anesthetized dogs, and the effects were compared with those of captopril.
Administration of MC 838 (0.1, 0.3, 1.0 and 3.0 mg/kg, i.v.) produced a gradual and dose-dependent decline in aortic pressure associated with no marked changes in coronary blood flow, heart rate and LVdP/dt. Captopril (0.01, 0.03, 0.1 and 0.3 mg/kg, i.v.) also caused a dose-related decrease in aortic pressure, but the significant hypotension appeared more rapidly than that of MC-838.
Both MC-838 and captopril inhibited selectively the pressor response to angiotensin I in a dose-related manner. The doses of MC-838 and captopril to lower mean aortic pressure by 10 mmHg from the pre-drug value were 2.8 mg/kg and 0.03 mg/kg, respectively; those of these drugs to cause 50% inhibition of angiotensin I-pressor response were 1.0 mg/kg and 0.04 mg/kg, respectively.
When administration of MC-838 (3.0 mg/kg) was repeated three times at a 30 min-interval, the second and third injections caused no additional hypotension, while each of the repeated injections of captopril (0.3 mg/kg) produced significant hypotension. These results indicate that MC-838 inhibits angiotensin I-conversion and decreases systemic blood pressure more slowly and persistently than captopril in anesthetized dogs.
it causes significant hypotension in normal volunteers (5). However, effects of MC-838 on the systemic and coronary circulation have not fully investigated.
Thus, this study was designed to evaluate acute hemodynamic effects of MC-838 and to compare them with those of captopril as a standard drug. As shown in Fig. 2 , adminis tration of MC-838 3 mg/kg, i.v., produced a gradual decline in aortic pressure without marked changes in coronary blood flow, heart rate and LVdP/dt. A pressor response to angiotensin I (50 ng/kg, i.v.) but not angiotensin 11 (20 ng/kg, i.v.) was apparently attenuated by MC-838 (Fig. 2 ). Significant hypotension was noted from 3 min after the administration of MC-838 (Table 1) by 9% of the control value at 10 min. As in the case of MC-838, administration of captopril decreased aortic pressure by 9% of the control value at 5 min, which was not accompanied by significant changes in coronary blood flow, heart rate and LVdP/dt except coronary vascular resistance (Table 1 ). Significant . Note that administration of MC-838 produces a gradual decline in aortic pressure (AoP) without affecting coronary blood flow (CBF), left ventricular dP/dt (LVdP/dt) and heart rate (HR), and it almost abolishes the pressor response to angiotensin I despite no change in angiotensin 11-induced response.
MCBF=mean coronary blood flow. hypotensive effect of captopril, however, was more rapidly revealed than that of MC-838 (Table 1) . Effects of MC-838 and captopril on responses of aortic pressure to angiotensin I, angiotensin II and norepinephrine are shown in Fig. 3 . The pressor response to angiotensin I reduced after administration of MC-838 or captopril in a dose-related manner, while those to angiotensin II tended to increase and those to norepinephrine did not alter sig nificantly when compared with the respective control value obtained before MC-838 or captopril (Fig. 3) .
The extent of hypotension induced by both inhibitors was dose-dependently increased, and it was closely related to that of inhibition of angiotensin I-induced pressor response, as shown in Fig. 4 . When calculated by using the method of least squares in linear regression, the doses of MC-838 and captopril to cause a decrease in mean aortic pressure by 10 mmHg from the pre-drug value were 2.8 mg/kg and 0.03 mg/kg, respectively; those of these drugs to cause 50% inhibition of angiotensin I-induced pressor response were 1.0 mg/kg and 0.04 mg/kg, respectively. The decreases in aortic pressure and percent inhibition of angiotensin I-pressor response produced by either inhibitor were significantly correlated (r=0.845, P<0.001, n=14; r=0.51 5, P<0.02, n=21, respectively). Fig. 5 . The first injection of MC-838 decreased significantly aortic pressure to 99±5 mmHg from the control of 113±5 mmHg. The second and third injections of MC-838, however, caused no additional decrease in aortic pressure (Fig.  5) . Percent inhibitions of angiotensin I pressor response after the first, second and third injections of MC-838 were 68±3%, 69±1% and 76±8%, respectively. On the other hand, significant decreases in aortic pressure were seen even after the second and third injections of captopril to a level similar to that after the first administration (Fig. 5 ), indicating that a partial recovery from the maximum hypotensive effect of captopril certainly occurred as early as 30 min after the injection. In addition, the maximum decrease in aortic pressure was seen within 10 min after captopril, while it was seen more than 10 min after MC-838. Percent inhibitions of the pressor response induced by angiotensin I after the first, second and third injections of captopril were 82±3%, 83±4% and 79±4%, respectively. These results clearly indicate that the hypotensive effect of MC-838 outlasts that of captopril which occurs more rapidly than MC-838. Three vertical broken lines indicate the time when the first, second and third injections of MC-838 or captopril were given, respectively. P<0.01 when compared with the control value obtained just before the injection of MC-838. *P<0.05, **P<0.01, when compared with the control value obtained just before each injection of captopril. MC-838 inhibited the pressor effects of angiotensin I in a dose-related manner, but not those of norepinephrine.
Discussion
In contrast to the case of angiotensin I, the pressor response to exogenous angiotensin II was significantly enhanced by the highest dose of MC-838. This observation can possibly be accounted for by a reduction in the level of circulating endogenous angiotensin II which is con sidered to cause an increase in the number of available angiotensin II receptors to result in enhancement of the responsiveness to exogenous angiotensin I I (11). Effects of MC-838 on the responses to angiotensin I, angiotensin II and norepinephrine were qualitatively similar to those of captopril, which are in accord with previous studies (6, 12). These findings indicate that MC-838, like captopril, may selectively inhibit con version of angiotensin I to angiotensin II in the systemic vasculature and thereby leads to vasodilation through reducing the circulating level of endogenous angiotensin II. Results that significant correlation between the hypotension and the inhibition of angiotensin I-response was seen after MC-838 adminis tration as shown in Fig. 4 may support this view.
Although it was not possible to determine the duration of the hypotensive action of MC-838 in this study, it seems reasonable that the effect of MC-838 on blood pressure appears longer in duration than that of captopril since an evident recovery from the maximum hypotension was seen 30 min after the administration of a large dose of captopril but not MC-838, as noted in Fig. 5 . Also, Table 1 and Fig. 5 show that the effect of MC-838 is slower in onset than captopril. mission (20, 21) . However, it is not known whether MC-838 has such effects. The role of the above effects other than inhibition of the renin-angiotensin system in the acute hemodynamic changes after captopril or MC-838 administration remains to be determined. Additionally, it may be necessary to consider the contribution of metabolite(s) of MC-838 in its hypotensive action, because MC-838 contains a captopril-moiety in its chemical structure.
In summary, the present experiments demonstrated that intravenous adminis tration of MC-838 produces inhibition of angiotensin I-conversion and decreases systemic blood pressure which appears more gradually and persistently when compared with captopril. However, extrapolations from the conclusions to clinical situations should be limited since findings in this study were obtained in the normotensively anesthetized dog.
